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ABSTRACT 
A Retrospective, Single-Institution Survey to Assess the Phenotype of Breast Cancer 
In Women Infected With the Human Immune-Deficiency Virus. 
L Langenhoven, P Barnardt. 
Department Medical Imaging and Clinical Oncology, Division Radiation and Clinical 
Oncology, Tygerberg Hospital, Parow. 
Background: HIV is the defining pandemic of our era, with an estimated 5.9 million people 
infected in South Africa according to World Health Organization (WHO) estimates for 2011. 
The expression and treatment of non-AIDS defining cancers has become an important 
consideration in this cohort, as antiretroviral therapy (ART) has prolonged survival in a 
subgroup previously at risk of early mortality. 
Study Design: A retrospective cohort study of all women seen at the Combined Breast 
Cancer Clinic at Tygerberg Hospital between January 2010 and December 2011, stratified 
into three subgroups based on HIV status.   
Methods: Of the 816 patients screened, 586 met inclusion criteria; of which 31 (5.3%) 
patients were HIV positive, 420 (71.7%) HIV negative, and 135 (23%) had an unknown HIV 
status. The disease phenotype was described in each subgroup, as well as toxicities 
associated with standard chemotherapy regimens, with an emphasis on completion rates of 
systemic cytotoxic treatment. The insult of cytotoxic therapy to the CD4 count was described 
for this cohort. 
Results: Women with HIV had a statistically significant (p<0.001) younger age at 
presentation of breast cancer with a median age of 42 years (range 39 – 45 years) in 
comparison with the HIV-negative cohort with a  median age of 54 years (range 53 – 55 
years) .  
No difference was detected in disease phenotype when stage at presentation (p=0.7874), 
histological subtype (p=0.3375), grade of differentiation (p=0.8297), nodal involvement 
(p=0.0998) or hormone-receptor positivity (p=0.6285) was considered. Completion rates for 
systemic chemotherapy were excellent (>90%) regardless of HIV-status and no statistically 
significant toxicity was observed. The median CD4 count at diagnosis was 477 cells/µL 
(range 234 – 807 cells/µL), with a nadir value of 333 cells/µL (range 62 – 713 cells/µL), 
representing a decrease of 30.2% during treatment. One case of suspected treatment-related 
mortality was recorded. 
Conclusion: This retrospective study confirmed that women infected with HIV had a younger 
age at breast cancer diagnosis when compared to women with a negative HIV-status. No 
difference in disease phenotype could be demonstrated for women with HIV, denoting the co-
existence of two common chronic diseases. Chemotherapy was tolerated well, but caused a 
median decline in CD4-count of 30% during treatment. 
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OPSOMMING 
‘n Retrospektiewe, Enkel-Instansie Oudit van die Borskanker-fenotipe in Vroue 
Geïnfekteerd met die Menslike Immungebrek-Virus (MIV). 
 
L Langenhoven, P Barnardt. 
Departement Mediese Beelding en Kliniese Onkologie, Afdeling Stralings en Kliniese 
Onkologie, Tygerberg Hospitaal, Parow. 
 
Agtergrond: Infeksie met die Menslike Immuungebrek-Virus (MIV) is die pandemie van ons 
era, met ‘n geraamde 5.9 miljoen mense geïnfekteerd in Suid-Afrika volgens die Wêreld 
Gesondheids-Organisasie (WGO) in 2011. Kankers wat nie met MIV geassosieer word nie, 
het n belangrike oorweging in hierdie populasie-groep geword as gevolg van die gebruik van 
anti-retrovirale terapie wat die lewensverwagting van mense met MIV verleng. 
 
Navorsingsontwerp: ‘n Retrospektiewe kohort studie van alle vroue wat tydens die tydperk 
Januarie 2010 en Desember 2011 by die Gekombineerde Borskanker Kliniek te Tygerberg 
Hospitaal behandel was, verdeel in 3 groepe volgens hul retrovirale status. 
 
Metodes: ‘n Totaal van 819 vroue was oorweeg vir insluiting in die studie, waarvan 586 aan 
die insluitingskriteria voldoen het. Daar was 31 vroue met MIV (5.3%), 420 vroue het MIV-
negatief getoets (71.7%), en 135 (23%) vroue waarvan die MIV-status onbekend was. Die 
fenotipe van borskanker was beskryf vir elke sub-groep, sowel as die toksiteite wat 
geassosieer word met die gebruik van standaard chemoterapie-skedules, insluitend die effek 
van chemoterapie op die CD4-telling. 
 
Bevindinge: Vroue met MIV het op ‘n statisties noemenswaardige (p<0.001) jonger 
ouderdom gepresenteer met borskanker (gemiddelde ouderdom 42 jaar, reikwydte 39 – 45 
jaar) in vergelyking met vroue wat MIV-negatief was (gemiddelde ouderdom 54 jaar, 
reikwydte 53 – 55 jaar). Geen verskil was waargeneem in die fenotipe van borskanker in 
vroue met MIV vir die stadium by diagnose (p = 0.7874), histologiese tipe (p=0.3375), graad 
van differensiasie (p = 0.8297), nodale betrekking (p = 0.0998) of hormoon-reseptor status 
(p=0.6285) nie. Voltooing van sistemiese chemoterapie is bereik in meer as negentig persent 
van gevalle onafhanklik van MIV-status. ‘n Gemiddelde CD4-telling van  477 selle/µL 
(reikwydte 234 – 807 selle/ µL) met diagnose het ‘n gemiddelde afname van 30.2% tydens 
behandeling getoon na ‘n  gemiddelde waarde van 333 selle/ µL (reikwydte 62 – 713 selle/ 
µL). 
 
Gevolgtrekkings: Hierdie retrospektiewe studie het bevind dat vroue met MIV op ‘n jonger 
ouderdom met borskanker presenteer as vroue wat MIV-negatief is. Geen noemenswaardige 
verskil was waargeneem in die fenotipe van borskanker in vroue met MIV nie, en dui daarop 
dat borskanker en MIV twee algemene, maar onafhanklike entiteite is. Chemoterapie was 
goed getolereer met ‘n  gemiddelde afname in die CD4-telling van 30.2% tydens 
chemoterapie. 
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CHAPTER 1: INTRODUCTION 
‘’It is estimated that 30 million lives have been lost globally to the human immune-deficiency 
virus (HIV) pandemic since 1981. ’’1 
Infection with the human immune-deficiency virus (HIV) is undoubtedly the defining pandemic 
of our era. According to the World Health Organization (WHO) Global HIV/AIDS Response 
Report 2011 an estimated 34 million people worldwide were living with HIV/AIDS in 2010.2 
Sub-Saharan Africa remained disproportionately affected with an estimated 22.5 million 
cases, representing 67% of the global HIV burden and of these, 5.9 million cases were from 
South Africa, the country with the largest population of people living with HIV/AIDS in the 
world.2  
The WHO estimated that 6.65 million people received anti-retroviral therapy (ART) in 2010, 
representing 47% of people eligible to treatment.2 In a recent article by May et al. it was 
shown that the life expectancy for people receiving ART increased by an average of 15 years 
between 1996 and 2008. When compared to the general population of the United Kingdom 
for this period, the decrease in average life expectancy amounted to only 13 years.3 
Although no concrete data is available to reflect the impact of ART in the South African 
setting, it is accepted that persons with HIV infection are living longer as a result of ART, and 
are hence at risk of developing illnesses associated with ageing, including chronic illnesses 
and malignancies.  
Data from the Swiss HIV Cohort Study showed that 19% of all cohort deaths in the ART-area 
were attributable to non-AIDS defining cancers (NADC).4 Much global effort is currently 
directed to describing the association between HIV and the NADC’s. An increased incidence 
was observed for anal cancer, lung cancer, certain head-and-neck cancers, hepato-cellular 
carcinoma, as well as Hodgkin’s Lymphoma, while for breast cancer, prostate cancer and 
colorectal cancer no increased risk was observed in the HIV-positive cohort. Very little is 
known on the phenotype of these malignancies in the context of HIV, as well as the outcome 
of patients receiving standard oncological treatment.5-10 
Given that breast cancer is the most common NADC to affect the global female population, 
affecting 1 in every 8 women in their lifetime,11  the question as to whether HIV- infection will 
alter the incidence, phenotype, response to treatment, or outcomes of breast cancer remains 
unanswered. It is expected that the complex interactions between a host with an altered 
immune-regulation, receiving ART, while being exposed to all the effects of ART will alter the 
course of breast cancer expression in the HIV-positive host. 
It is the primary objective of this retrospective cohort study to describe the phenotype of 
breast cancer in women diagnosed with HIV in comparison to the HIV-negative control group. 
LITERATURE REVIEW 
A PubMed literature review restricted to the English language was performed using the 
keywords ‘HIV’ and ‘breast cancer’ for the period 1981 to present. It is of interest that our 
current understanding of breast cancer in the HIV-positive patient is based on case series 
detailing single institution experience. 
Amir et al. published data from the Tanzanian Cancer Registry and concluded that a 
statistically significant decreased incidence of breast cancer was observed for both men and 
women before and during the AIDS-pandemic.12 These results have been replicated by large 
Stellenbosch University  http://scholar.sun.ac.za
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cancer registry based studies in Italy, France and the USA and possible explanations 
include:13-15 
a) The competing mortality of opportunistic infections – patients do not live long 
enough to develop breast cancer, and succumb to HIV-related complications. 
b) The possible underreporting of cases in the third world reflecting decreased 
access to health care and socio-economic status, and 
c) The overall reduced risk in the developing world for breast cancer when the 
following known protective factors for breast cancer are considered: 
i. Early age of first childbirth 
ii. High parity 
iii. Low alcohol intake 
iv. Lower social status. 
According to the heterotypic model of carcinogenesis, it is postulated that decreased 
immunity associated with HIV-infection might be protective in developing breast cancer.16,17 A 
recent report on HIV-1 and glycoprotein-120 (gp120) induction of breast cancer cell apoptosis 
through gp120-CXCR4 receptor supports this theory.18  Further reports have shown ritonavir 
to inhibit breast cancer growth through the inhibition of Akt-regulated cell proliferation.19 
Currently any assumption made as to the protective/permissive role of HIV in the 
development of breast cancer would be premature. In clinical practice it is accepted that HIV 
is not permissive to the development of breast cancer and that the incidence of breast cancer 
in the HIV-positive person is the same, or slightly less than their congruent background 
populations.  
Evidence to support a more aggressive breast cancer phenotype with poor outcome was 
presented by Guth in a case series of 17 patients published in 1999 in which 14 patients had 
metastatic disease at presentation and an associated poor outcome.20 Yet, this uniformly poor 
outcome could be greatly attributed to the following confounders: 
Most cases were managed before the ART-era and represent a cohort of patients with 
progressive immune-impairment, prone to the development of opportunistic infections, and a 
poor tolerance of systemic chemotherapy due to the associated rise in viral load during 
treatment. Patients in the cohort were mostly young African-American women, a subgroup 
known to have a uniformly poor outcome, younger age at presentation and more advanced 
disease stage at diagnosis. Furthermore, poor socio-economic status is an independent risk 
factor for both HIV-infection and lack of access to mammography screening, and may 
represent a confounding effect in advanced stage at diagnosis. 
Evidence to support a similar phenotype to that seen in the HIV-negative patients comes from 
a series published in 2000 describing the outcome of 20 consecutive patients treated at the 
Jackson Memorial Hospital in Miami.21 Of interest was that 12 of the 20 patients presented 
with early stage disease, and the stage distribution was similar to the HIV-negative cohort. 
The most important contribution made by this study was the inclusion of toxicity data in 
relation to the tolerance of chemotherapy. Hurley cautioned that doxorubicin-based 
chemotherapy was poorly tolerated in the HIV-positive patient, with a higher incidence of 
grade 3 and 4 toxicity observed including neutropenic sepsis, Candida esophagitis and Adult 
Respiratory Distress Syndrome (ARDS). 21 
The overall survival in patients treated with chemotherapy was inferior to patients only offered 
hormonal therapy in both the adjuvant and metastatic setting. Hurley postulated that 
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chemotherapy dealt a blow to the immune-system that could not recover after the completion 
of chemotherapy and was permissive to the progression of the HIV-infection and early 
HIV/AIDS related mortality.21 
These findings were supported by another series of five HIV-positive women with breast 
cancer published in 2002.22 Eighty percent of patients developed grade 3 or 4 neutropenia, 
with one mortality due to neutropenic sepsis while two patients developed progression of their 
HIV-infection as confirmed by a rise in the HIV-1 RNA viral load. Both doxorubicin and 
taxane-based chemotherapy were poorly tolerated. The recommendation was to introduce 
the routine use of supportive prophylactic granulocyte-colony stimulating factor (G-CSF). 
More recent data published by Sarhan et al. details the experience of the Harlem Medical 
Centre for the period 2002 to 2008.23 The phenotype of six HIV-positive women was 
compared to that of 57 negative women from the same cohort (n=63). No difference in stage 
at presentation, age, tumour morphology or outcome was observed between the two sub-
groups. Chemotherapy was tolerated without significant toxicity, and the 5-year overall 
survival for the HIV-positive cohort was 75%. A major confounder became evident when the 
stage distribution was considered: only 34% of patients presented with stage 3 or 4 disease. 
This phenomenon was attributed to increased access to health care associated with the 
routine follow-up of HIV infected patients. 
STUDY OBJECTIVES 
Primary objective: It was the aim of this study to describe the phenotype of breast cancer in 
the HIV-positive population in relation to the HIV-negative control group. Attention was paid to 
the pattern of disease expression, and in particular the age at diagnosis, stage of 
presentation, hormone-sensitivity of the tumour, as well as markers of biological 
aggressiveness including the grade of differentiation, presence of nodal metastases and 
histological subtype. 
Secondary objectives: 
1. The ability of HIV positive patients to complete standard chemotherapy regimens. If 
planned treatment could not be completed, the reasons for cessation and the timing 
thereof were documented. 
2. Acute toxicities were noted. 
3. The trend of CD-4 count changes during chemotherapy was described. 
STUDY DESIGN 
This was a retrospective cohort study of all female patients seen at the Combined Breast 
Clinic at Tygerberg Hospital for the period January 2010 to December 2011. Consented HIV-
testing was introduced in 2009, and despite attempts to attain 100% testing, the status of 
some patients were unknown. The cohort was divided into three sub-groups reflecting the HIV 
status of the patient: HIV-negative, HIV-positive, and HIV-unknown. All variables were 
compared between the three subgroups to determine whether a statistically significant 
difference could be detected when considering the phenotype of disease or outcome of these 
sub-groups. 
INCLUSION CRITERIA 
1. All patients newly diagnosed with breast cancer at Tygerberg Hospital during the 
period January 2010 to December 2011 were eligible for inclusion. 
Stellenbosch University  http://scholar.sun.ac.za
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2. Patients were female and aged between 18-100 years.  
3. Patients of all ethnic groups were eligible for inclusion. 
 
EXCLUSION CRITERIA 
1.  Benign or non-invasive disease. 
2.  Patients with insufficient data. 
3.     Male patients with breast cancer. 
 
RESOURCES 
Funding to the monetary value of R16 500 was made available through the D43 grant in lieu 
of the salary for the data capturer.  
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CHAPTER 2: METHODS 
STUDY DESIGN: 
A retrospective analysis was performed of all women registered at the Combined Breast 
Clinic at Tygerberg Hospital for the period January 2010 to December 2011. A total of 819 
patients were seen during the trial period, of which 586 met the inclusion criteria. Exclusions 
were for: insufficient data (n=154), prior diagnosis of breast cancer (n=47), male gender 
(n=11), ductal carcinoma in situ (n=16) and benign breast disease (n=5). 
RESEARCH PROCEDURES: 
The demographic profile was considered in each subgroup as primary endpoint, and reported 
in terms of median age at presentation, HIV-status by ethnic group, menopausal status and 
Breast Cancer Gene (BRCA) status. 
The disease phenotype was described in terms of stage at presentation (Breast cancer was 
staged according to the American Joint Committee on Cancer (AJCC) staging system 2007), 
25
 histological subtype, grade of differentiation, nodal status and hormone-receptor positivity 
for the estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth 
factor 2 (Her-2) receptor respectively. 
Secondary objectives included the ability of patients to complete the number of intended 
chemotherapy cycles scheduled at the start of treatment. Allowance was made for 
interruptions or postponements due to any cause, as well as dose reductions due to toxicities. 
A patient was considered to have completed chemotherapy if the total number of cycles 
completed were in agreement with the number of cycles planned at the onset of treatment. A 
comparison was made between the completion rates of the respective subgroups. 
The HIV-positive subgroup was considered separately in so far chemotherapy toxicity data 
was concerned, and scoring of toxicities were done according to the European Organization 
for Research and Treatment of Cancer (EORTC) Common Toxicity Criteria (CTC) Scoring 
system, version 4.0 24 A toxicity grading was assigned for each patient at each cycle for the 
following hematological parameters: hemoglobin (Hb), white cell count (WCC), platelets, 
neutrophils, lymphocytes and CD4 count. Clinical toxicities considered were for nausea and 
vomiting, alopecia, thrombophlebitis and loss of weight. A concise case report was offered for 
each patient who could not complete chemotherapy as planned, detailing the specific reasons 
for cessation of therapy. 
The CD4-nadir was defined as the lowest value recorded during or at any stage after 
treatment, and reported as a mean value with a standard deviation, minimum and maximum 
values. It is practice at Tygerberg Hospital to repeat the CD4 value at cycle 3 and on 
completion of chemotherapy. The timing of the nadir values reflected this practice. 
Data collection commenced on 13 March 2012 when ethical approval was obtained and 
included all potential patients from 14 January 2010 up to 31 December 2011 when data lock 
occurred. 
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DEFINITIONS: 
Breast Cancer Gene (BRCA): Indications for Breast Cancer susceptibility gene 1 and 2 
(BRCA) testing include: 
o Breast cancer in women younger than 35 years old. 
o A family history of breast cancer involving a first-degree relative. 
o Male breast cancer. 
o Bilateral breast cancer. 
Completion of chemotherapy regimen as planned: Completion of the total number of 
chemotherapy cycles as planned despite postponements and/or dose-reductions made.  
Early-stage breast cancer: Defined as all patients with disease that has not spread beyond 
the breast or axillary lymph nodes, and include patients presenting with Stage I and II disease 
according to the American Joint Committee on Cancer (AJCC) Staging system. 25 
HIV-positive: The serum HIV Enzyme Linked Immunosorbent Assay (ELISA) 
Antigen/Antibody Combination Assay test for the presence of both HIV antibody and antigen 
(p24) was used. Positive serologic results were repeated and patients were deemed HIV-
positive if serum positivity was confirmed with 2 separate ELISA tests. 
Locally advanced disease: Defined as all patients presenting with stage III breast cancer 
according to the AJCC Staging system. 25 
Menopausal status:  
Menopause: A physiological occurrence marking the permanent cessation of ovarian function 
in women with an intact uterus (medical menopause) or without (surgical menopause), 
usually occurring during the late 40’s or early 50’s. Post-menopausal status is reached when 
no menstrual cycles are recorded for 12 consecutive months in the absence of pregnancy, 
lactation, or other pathological causes of amenorrhea.  
Peri-menopause is descriptive of the period around menopause, where menstrual cycles are 
less frequent and less predictable in women in midlife, but not meeting the above criteria. 
Pre-menopause: Intact ovarian function in women of reproductive age. 
Nodal sampling: The surgical evaluation of axillary lymph nodes as appropriate in non-
metastatic patients, including sentinel lymph node biopsy and axillary clearance. 
Performance status: All patients were scored according to the Eastern Cooperative 
Oncology Group (ECOG) performance status scoring system.24 
Range: The median age range was defined as the age that marks the -95% and +95% 
centiles respectively. 
Stage: Breast cancer was staged according to the AJCC staging system 2007.25 
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DATA CAPTURING AND SAFETY: 
Data acquisition was performed at the Gene Louw Building at Tygerberg Hospital by the 
principal investigator and data capturer following protocol approval by the Health Research 
Ethics Committee 1 (HREC-1). Approval to conduct research at Tygerberg Hospital in 
accordance with the Provincial Research Policy and Tygerberg Hospital was granted. 
Data was captured onto a password-protected database, with access restricted to the 
principal investigator, data capturer and supervisor. The format of the database was designed 
by Prof. Martin Kidd to facilitate statistical analysis subsequent to data acquisition. Patient 
confidentiality was protected through the use of registry numbers to which only the principal 
investigator has access. The datasheet is attached as Addendum 7. 
DATA ANALYSIS: 
Statistical analysis was performed by Prof Martin Kidd at the Centre for Statistical 
Consultation, Stellenbosch University. The completed database was imported into the 
Statistica software program, which was used for data analysis. Prior to data analysis, all 
variables were reviewed for incomplete data. Where data was missing, an ‘unknown’ variable 
was created.  
Descriptive data analysis was utilized in nominal variables such as age, as well as ordinal 
variables for race, menopausal status, stage at presentation and histological subtype. 
Histograms, graphs and tables were utilized in data-representation. Hypothesis testing was 
done through linear regression models, Chi-square and ANOVA analysis, and expressed in 
terms of a p-value for which a p<0.05 was considered to be statistically significant. 
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CHAPTER 3: RESULTS  
A total of 586 patients were included in the study from January 2010 to December 2011, of 
which 31 (5.3%) were HIV-positive, 420 (71.7%) were HIV-negative, and 135 (23%) had an 
unknown HIV status. The median age at presentation was 56 years, with a standard deviation 
(SD) of 14.1 years and a range of 20 to 97 years. The majority of women were from a Mixed 
Race, representing 61% of the cohort. Approximately a third of women (27%) were of 
European descent, while 12% was of African descent, reflecting the referral pattern and 
drainage areas for our institute. Bilateral breast cancer was observed in 20 patients (3%), with 
the remainder having an equal chance of having a left- (48%) or right-sided (49%) tumor. 
A statistically significant age difference (p<0.001) was detected between the three subgroups, 
favoring a younger age at presentation for women infected with HIV. The median age at 
diagnosis for the HIV-positive subgroup was 42 years, a median age difference of 12 years 
when compared to the HIV-negative subgroup, and 19.5 years when compared to the 
subgroup with an unknown HIV-status (Graph 1). The age range between the 95th centiles 
was much smaller for the HIV-positive subgroup (7.5 vs. 13.1 years) when compared to the 
HIV-negative subgroup, denoting a more homogenous age distribution (Table 1). 
HIV- status         Positive        Negative        Unknown   
  
 
n = 31 % 
 
n = 420 % 
 
n = 
135 %   
Median age      
            
Diagnosis  (years)   42     54,3     61,8     
Range (95th 
centiles)   39-45     53-56     59-64     
African   40     48,7     63,4     
Mixed race   45     54     59,3     
European     -     57,6     64,9     
  
         
  
Ethnic group 
 
        
  
Mixed race 
 
13 3,6 
 
272 75,8 
 
74 20,6   
African 
 
18 26,1 
 
43 62,3 
 
8 11,6   
European 
 
0 0 
 
105 66,4 
 
53 33,6   
  
         
  
Menopausal status     
            
Pre-menopausal   20 64,5   143 34,1   37 27,4   
Post-menopausal   7 22,6   271 64,5   97 71,9   
Peri-menopausal   4 12,9   6 1,4   1 0,7   
  
         
  
BRCA-receptor status 
  
     
  
Not done 
 
28 90,3 
 
369 87,9 
 
125 92,6   
Positive 
 
0 0 
 
10 2,4 
 
1 0,7   
Negative 
 
3 9,7 
 
41 9,7 
 
9 6,7   
                      
 
Table 1: Demographic data by HIV-status 
 
In the subgroup stratification the HIV-status was known in 77% (n=451) of the cohort, of 
which 6.9% (n=31) of women tested positive for infection with HIV.  The HIV-status was not 
determined in 23% of patients (n=135). A subgroup analysis was performed based on ethnic 
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group to address a possible confounding effect inherent to the association between HIV
positivity and ethnic group (Table 1). A statistically significant (p<0.01) younger age at 
presentation was seen for women infected with HIV after 
infected with HIV presented on average 8.2 years earlier when compared to the HIV
subgroup, and 22.9 years when compared to the HIV
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analysis it was found that (Table 1):
1. No case of HIV
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20,6% of patients not tested for HIV, while
3. The proportion of patients with HIV
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Figure 
Based on standard criteria, BRCA testing was performed in 11% of the cohort, with
BRCA-positive result recorded
observed in the frequency with which BRCA status was determined
No statistically significant difference in stage at presentation was observed between the 
subgroups (p=0.7874), despite a
the HIV-positive subgroup. The majority 
early-stage breast cancer, with locally advanced and metastatic disease representing 39% 
and 14.6% of cases respectively. A trend towards advanced disease at presentation became 
evident for the HIV-positive subg
equal proportion of patients presented with early and metastatic disease. When the HIV
unknown subgroup was considered the majority of patients (43.4%) presented with early 
breast cancer. 
Infiltrating duct carcinoma was the predominant histological s
regardless of HIV-status, and 
82.1% (HIV-unknown) of all cases. Infiltrating lobular carcinoma was
recorded histological type. The remaining histological subty
‘other’ due to the small number of events and unsure statistical significance when considered 
in isolation.  
A significant percentage of HIV
as ‘other’ at presentation in contrast to the HIV
subgroups, but due to small numbers, this finding did not reach statistical significance. The 
subtypes classified as ‘other’ were reviewed
the following histologies:  
A cytological diagnosis had not been made in one patient due to a poor performance status at 
disease presentation, while another patient defaulted management prior to confirmatory 
cytological testing. The remaining five cases were 
mucinous adenocarcinoma (n=1)
still of epithelial origin, and not the less frequently
or inflammatory breast cancer
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No statistically significant (p=0.8297) difference in tumor differentiation was observed 
between the subgroups and ≈30% of patients presented with moderately differentiated 
tumours (grade 2).   
In patients offered axillary sampling (58,1%), the majority of patients (78%) had less than four 
nodes involved, with no statistically significant difference (p=0.0998) detected between the 
subgroups. Her-2 receptor positivity to the human epidermal growth factor receptor-2 (HER-2) 
neu-oncogene was equally represented between the subgroups, being positive in a third of 
the patients in line with internationally expected 20-30% incidence of all breast cancer cases. 
 
HIV-status         Positive        Negative   p-value   
  
 
n = 31 % 
 
n = 
420 %  
 
  
Stage at presentation 
                
Stage 1   2 6,5   21 4,9       
Stage 2   8 25,8   174 41,5   p=0.7874   
Stage 3   11 35,4   164 39       
Stage 4   10 32,3   61 14,6       
  
        
  
Histological subtype 
       
  
Infiltrating ductal carcinoma 22 71 
 
355 84,9 
  
  
Lobular carcinoma 2 6,5 
 
28 6,7 
 
p=0.3375   
Other  
 
7 22,5 
 
35 8,4 
  
  
  
        
  
Grade of differentiation 
                
Well differentiated 3 9,7   38 9,1       
Moderately differentiated 9 29   119 28,3   p=0.8297   
Poorly differentiated 5 16,1   89 21,2       
Unknown differentiation  14 45,2   174 41,4       
  
        
  
Nodal 
Status  
       
  
Total 
sampled  15   265   
 
  
< 4 nodes involved 13 86,7 
 
182 68,7 
 
p=0.0998   
≥ 4 nodes involved 2 13,3 
 
83 31,3 
  
  
  
        
  
Hormone Receptor 
Status                 
Estrogen Receptor 
positivity 16 51,6   268 63,8       
Progesterone Receptor 
positivity 9 29   215 51,2   p=0.6285   
HER-2 Receptor positivity 10 32,3   149 35,5       
                    
 
 
Table 2: Disease and tumour characteristics by HIV status 
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Figure 
No statistically significant difference (p=0.62585) in hormone receptor sensitivity was 
observed between the subgroups, b
for the HIV-positive subgroup. Estrogen 
51.6% of patients in contrast to the 63.8%
difference between the subgroups was 
receptor (PR) was considered.
positive disease, in contrast to the 51.2% of the HIV
 
TREATMENT DEMOGRAPHICS
The administration of systemic 
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HIV-unknown (11%) cohorts
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flourouracil (CMF) regimen was reflective of individual patient characteristics, especially 
cardiac compromise, a known contra
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3: Nodal involvement by HIV status 
ut slightly less hormone-sensitive disease was observed 
receptor (ER) positive disease was observed in 
 in the HIV-negative subgroup. An even greater 
observed when sensitivity to the Progesterone 
 Only 29% of the HIV-positive subgroup presented with PR
-negative subgroup. 
 
chemotherapy was predominantly in the neo
-positive, 37% of the 
-unknown subgroups receiving neo-adjuvant chemotherapy 
significant difference was observed when the administration of 
-positive (10%), HIV-negative (14%) and 
 (p=0.1662).  
ment of breast cancer, 
based regimen in combination with cyclophosphamide and/or 5
 of patients regardless of HIV-
-based therapy in the cyclophosphamide/methotrexate/5
-indication to the use of systemic anthracyclines.
py regimens was considered, no statistically 
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HIV-status     Positive      Negative 
  n = 20 %   n = 228 % 
Regimen completed 17 85 
 
212 93 
Regimen not completed 3 15 
 
16 7 
            
 
 
Table 3: Chemotherapy completion rates 
 
 
THE HIV-POSITIVE SUBGROUP: 
TREATMENT DEMOGRAPHICS  
The HIV-positive cohort constituted 31 female patients, of which 20 patients were offered 
systemic chemotherapy. The majority of patients (78.1%) had a performance status graded 
as ECOG 0 or 1 at presentation, with performance status 2 and 3 observed in 6.3% and 9.4% 
of cases respectively. Five patients absconded after staging examinations were completed 
and prior to any treatment. Medical contra-indications precluded the use of chemotherapy in 
five patients, with the remaining patient not offered systemic cytotoxic therapy on the basis of 
early breast cancer. 
The majority of patients (n=22) were known to be HIV-positive at diagnosis, with the 
remainder (n=9) being diagnosed at their first clinic visit. The mean CD4 count at diagnosis 
was 402 cells/µL, with a standard deviation of 244 cells/µL and a range of 66 to 1075 cells/µL. 
The CD4 nadir was not recorded in five patients and were subsequently excluded from the 
nadir value analysis.  A CD4-value greater than or equal to the value at initiation of 
chemotherapy was observed for two patients, one patient who had started ART at diagnosis 
of her breast cancer, while the ART regimen of the second patient was changed to second-
line therapy. When the use of ART was considered, only 12 patients (37.5%) had been on 
ART for three months or longer. The remainder of patients was referred for initiation of ART at 
the start of chemotherapy. 
Co-morbid infections were present in 12.9% of patients at diagnosis, represented by 
Pulmonary Tuberculosis (PTB) (n=2), Aspergillosis (n=1) and Staphylococcus aureus 
pneumonia (n=1). 
 
CHEMOTHERAPY TOXICITY DATA 
Chemotherapy was administered in the neo-adjuvant (n=15), adjuvant (n=3), and palliative 
(n=2) settings and was generally well tolerated in the majority of patients. The most common 
toxicities observed were alopecia (n=16), nausea and vomiting (n=15), thrombophlebitis (n=3) 
and asthenia (n=3).  
Hematological toxicities were predominantly limited to grade 0 and 1, with grade 3 or 4 
toxicities commonly witnessed in the lymphocyte count (Table 4). The grade 4 hemoglobin 
toxicity observed in one patient (5.3%) was contributed to the additive suppressive bone 
marrow effect of Cyclophosphamide in combination with ART. No grade 3 or 4 toxicity was 
observed for the white cell- or platelet count. The depletion of the lymphocyte count innate to 
HIV infection was exacerbated by systemic cytotoxic therapy, with grade 3 and 4 toxicities 
witnessed in 26.4% of patients, representing the most frequently observed asymptomatic 
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hematological toxicity. Only two patients (10.5%) had grade 3 toxicity of the neutrophil count, 
which did not preclude the successful completion of chemotherapy. 
 
Toxicity        Grade 0        Grade 1/2      Grade 3/4 
  
 
n  % 
 
n % 
 
n % 
  
Hemoglobin   1 5,3   17 89,4   1 5,3 
  
White cell count 
 
16 84,2 
 
3 15,8 
 
0 0 
  
Platelets   19 100   0 0   0 0 
  
Neutrophil count 
 
12 63,2 
 
5 26,3 
 
2 10,5 
  
Lymphocytes   2 10,5   12 63,1   5 26,4 
  
                      
 
Table 4: Hematological toxicities scored by EORTC grading system 24 
 
The administration of planned chemotherapy was not accomplished in three patients. The first 
patient defaulted mid-chemotherapy and returned 7 months later when she presented with 
local progression of her breast cancer (ulceration, fixation to chest wall and uncontrolled pain) 
and was offered palliative neutron external beam radiotherapy. The second patient was 
offered palliative systemic therapy for stage IV disease and completed 4 cycles prior to 
defaulting treatment. Collateral history suggested she died due to possible chemotherapy-
related toxicity. The third patient was offered neo-adjuvant chemotherapy but developed 
progression of her disease (contra-lateral breast involvement) after four cycles of 
chemotherapy and was offered palliative radiotherapy.  
Although not affecting the completion of planned chemotherapy, two patients required an 
adjustment to their ART-regimen during chemotherapy. Grade 4 anaemia was witnessed in 
one patient, with a second patient requiring an adjustment in ART due to decreased renal 
function as reflected by a deterioration in her glomerular filtration rate (GFR). One patient 
necessitated the initiation of bactrim® (trimetoprimsulphametoxazole) prophylaxis when her 
initial CD4 count (466 cells/µL) dropped below 200 cells/µL. She received ART for more than 
three months at time of her diagnosis. Transport problems delayed treatment in two patients 
but both managed to complete planned chemotherapy. 
Only patients with completed CD4 values (n=16) were included in data analysis utilizing the t-
Test for dependent means (Figure 4). A statistically significant difference (p=0.0002) was 
detected in the mean CD4-count when measured at the start of treatment (477 cells/µL), and 
the lowest recorded value (333 cells/µL).   
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Figure 4: Mean change in CD4-count. 
The observed decrease in median CD4 count amounted to 30.2% of the pre-treatment value. 
The Standard deviation (SD) remained consistent when pre-treatment (SD=160 cells/µL) and 
nadir (SD=166 cells/µL) values were considered, denoting a homogeneous insult to the CD4 
value during chemotherapy treatment.  
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CHAPTER 4: DISCUSSION 
A statistically significant younger age at presentation (p<0.001) was evident in our cohort for 
women infected with HIV after correcting for ethnic group, supporting the notion that these 
women were at least a decade younger (42 vs. 54 years) than their HIV-negative 
counterparts at the time of their breast cancer diagnosis. Yet, the interpretation of this finding 
was one of the most contentious aspects in the literature. Many authors put forth arguments 
to explain this phenomenon per se, but it was unlikely that any one explanation would suffice 
in explaining this phenomenon, rather it was expected that the symbiotic interaction of 
different factors were responsible for the observed younger age at presentation. 
The majority of published case reports detailed the outcome of African American women, a 
cohort known to have a younger age at diagnosis, more aggressive disease and a universally 
poor outcome in comparison to other ethnic groups. The fact that the majority (59.4%) of HIV-
positive patients in our cohort were of African descent was the first factor contributing to the 
younger age at diagnosis as witnessed in this retrospective study. A younger age at 
presentation was described by Voutsadakis, arguing that age at presentation reflected the 
younger age of women infected with HIV.31 When considering the South African HIV 
prevalence data, the highest prevalence was recorded in African women of reproductive age 
and supported this theory, the second factor to underlie the anticipation of age at diagnosis 
witnessed in our cohort. 28,29 
HIV remains a highly stigmatized entity in the South African context, with a resultant negative 
impact on the accurate reporting of prevalence data. Current HIV infection estimates are 
based on indirect measures such as ante-natal incidence data, shifts in mortality patterns, as 
well as the analysis of annual surveys.28,29 The reported national prevalence of HIV in women 
aged 55-59 years, was 7.7%, a figure not too dissimilar to the observed 5.4% in our cohort, 
especially when considering that 22% of the cohort was not tested for HIV. Only when 
prevalence data was considered by age group, did the dilutional effect of the predominantly 
older patient with breast cancer become evident.  
Nearly a third of European women were not screened for HIV, while 11.6% of African women 
had an unknown HIV status. Possible explanations included the fact that African women have 
a younger median age at presentation and were screened more vigorously due to their 
reproductive status. Women of African descent are known to have the highest prevalence of 
HIV, hence influencing screening bias at first consultation. 26,27 Of the African subgroup, 
26.1% of women tested positive for HIV, with a median age of 40 years (range 39 - 45 years). 
The background HIV prevalence in Western Cape for this cohort was 18.5% in 2010.27 
Whether this observed increased prevalence represented a true excess of women with HIV 
and breast cancer was uncertain. The prevalence of HIV in the Mixed Race and European 
subgroups was less than the expected national average, but still congruent to the background 
age per race stratification. The disproportionate burden of HIV infection in the African 
subgroup reflected the epidemiology of HIV infection in Southern Africa, currently the target of 
interventions aimed at understanding and controlling the pandemic.  
No statistically significant difference (p=0.36294) was observed in the frequency with which 
BRCA status was determined. In line with recorded experience, 19.6% of the HIV-negative 
subgroup tested positive for an alteration in the BRCA gene.29 When considering the 
advanced median age at presentation of the HIV-unknown cohort, 10% of patients tested 
positive for the BRCA-gene. Due to the younger age at presentation of HIV-positive patients, 
an expected increase incidence of BRCA-1 and BRCA-2 gene mutations would be observed 
in this subgroup. Yet, no statistically significant difference was detected, and no HIV-positive 
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patient tested positive for the germline mutation for BRCA1 or BRCA2 genes. The notion that 
younger age at presentation might be due to a hereditary trait was thus excluded. 
No statistically significant difference (p=0.62585) in hormone receptor sensitivity was 
observed between the subgroups, but a trend towards less hormone-sensitive disease was 
observed for the HIV-positive subgroup. This finding was thought to be representative of the 
fact that hormone-sensitive tumours are generally associated with women of post-
menopausal status, in this case, women with HIV-negative and HIV-unknown status 
No statistically significant difference was detected in stage at presentation, histological 
subtype and grade of tumour differentiation, presence of nodal metastases or lymphovascular 
invasion when disease presentation in women with HIV was contrasted to women who were 
HIV negative or had an unknown HIV status. The notion that HIV altered the phenotype of 
disease expression was thus rejected, and in accordance with the phenotype described by 
both Sarhan and Hurley.21, 23 
Chemotherapy was tolerated well in all subgroups regardless of HIV status, with completion 
rates in excess of 90%. Five patients absconded after staging examinations were completed 
and prior to any treatment. The high rate of patients absconded prior to treatment was 
contributed to the multiple socio-economic confounders associated with HIV infection and 
ethnicity. Our finding of high chemotherapy completion rates was in contrast to earlier case 
reports where adverse outcomes were reported for systemic anthracycline-based cytotoxic 
therapy, including neutropenic sepsis, ARDS, Candida Oesophagitis and death.21, 22, 33 It was 
thought that the careful selection of HIV-positive patients receiving chemotherapy contributed 
to excellent completion rates, as well as the fact that patients were started on ART at initiation 
of chemotherapy regardless of CD4 count as per national ART treatment guidelines.  
Grade 3 and 4 myelosupression as reported in the literature was replicated only in so far 
lymphopenia was concerned, where 26.4% of the HIV positive cohort presented with grade 3 
and 4 lymphopenia. This finding represented the synergistic effect of HIV and chemotherapy 
on the lymphocyte population. No dose adjustments were made for this toxicity and no 
resultant impact on treatment completion ensued. No dose-limiting toxicity was observed in 
the neutrophil count, with only 10.5% of patients developed grade 3 neutropenia. A single 
case of grade-4 toxicity was observed in the Hemoglobin levels of a patient, and contributed 
to the additive effect of chemotherapy and ART on bone marrow. No case of platelet toxicity 
was reported, with 100% of values graded as grade 0. 
A single case of suspected treatment related mortality was observed in this cohort, but could 
not be confirmed by special investigations as the patient did not present to a medical 
institution prior to her demise. This incident was thought to elude to a much greater problem 
underlying the administration of cytotoxic therapy in patients with HIV – the fact that infection 
with HIV serves as a proxy for poor socio-economic means, a problem further compounded 
by language barriers and cultural beliefs.   
No case of breast cancer was diagnosed at a CD4 value below 200 cells/µL and supported 
the notion that infection with HIV was neither permissive nor protective to the development of 
breast cancer, but rather represented the co-existence of two common chronic diseases. To 
date, the only association between CD4 count and the relative risk of developing a 
malignancy was shown in cancers with a viral pathogenesis, the so-called AIDS-defining 
cancers. No association between progressive immune-suppression as witnessed by a 
decreased CD4 count was shown for the NADC’s, a finding echoed in our study population.  
Lymphoma studies published during the pre-ART era established the perception that 
chemotherapy administered in the HIV setting led to persistent, severe compromised 
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immunologic function and poor outcomes.32 The results of the AIDS malignancies consortium 
trial 010 confirmed an excess of deaths attributable to opportunistic infections, post-
chemotherapy in patients with CD4 counts <50 cells/µL.33 However, a declined mean CD4 
count was reported in trials but recent studies confirmed that chemotherapy was tolerated 
without significant opportunistic toxicity in the ART setting despite initial low CD4 counts.34, 35, 
36 In our study the observed decrease in CD4 count amounted to a third of pre-treatment 
values, with a mean CD4 count at diagnosis of 477 cells/µL (234-807 cells/µL) in comparison 
with a mean nadir CD4 count of 333 cells/µL (62-713 cells/µL).  
STRENGTHS & LIMITATIONS 
Describing the phenotype of breast cancer in the HIV positive patient is ideally suited to the 
South-African academic environment, as South Africa currently has the highest HIV 
prevalence in the world. The excellent administrative system at the Combined Breast Clinic 
formed an ideal basis for retrospective data analysis, especially given the limitations inherent 
to retrospective data analysis. 
The retrospective nature of data collection formed the greatest limitation of this study, with 
missing data and a non-uniform reporting of side effects evident at the time of data capturing. 
CD4 values were not determined at set intervals on completion of treatment, hence no 
recommendations could be made regarding the concern that systemic chemotherapy leads to 
progression of HIV itself and subsequent poor outcomes.  
A prospective study evaluating the recovery of the CD4 nadir in terms of timing and absolute 
values should be undertaken to address this issue. The observed frequency of poor 
compliance, haphazard attendance and patient absconding during treatment were contributed 
to socio-economic and cultural issues and was a major limitation in patient access to health 
care. The triad of poor socio-economic means, strong cultural beliefs and the effects of a 
language barrier became evident as confounding factors, as witnessed in the unacceptably 
high rates of recorded defaulting for the HIV-positive subgroup. 
A shortcoming in the reporting of CD-4 toxicity values became evident when utilizing the 
EORCT-CTC system, as CD4-values are reported in terms of absolute values, and no 
allowance is made to capture the percentage decline in CD-4 count during therapy. The 
EORCT-CTC version 2 was used to score toxicity in this study, but on evaluating the 
differences between the earlier and later versions, the subtle changes in toxicity definitions 
did not translate to a different statistical result, mainly as a result of grouping low grade (grade 
1&2) and high grade (grade 3&4) toxicities together. 
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CHAPTER 5: CONCLUSION 
This retrospective study confirmed that women infected with HIV presented at a younger age 
with breast cancer (42 years; range 39– 45 years) when compared to women with a negative-
HIV status (54 years, range 53 – 55 years). This finding was attributed to the younger age of 
women infected with HIV and the predominant African ethnicity of the HIV-positive subgroup, 
a known risk factor for a younger age at presentation.  
No difference in disease phenotype could be demonstrated for women with HIV, denoting the 
co-existence of two common chronic diseases. Systemic chemotherapy was tolerated well in 
women infected with HIV, attributable to the careful selection of patients offered 
chemotherapy and the fact that all newly diagnosed HIV-patients were offered ART at their 
breast cancer diagnosis.  
No statistically significant chemotherapy toxicity was observed and no patient developed 
opportunistic infections during treatment. The mean decline in CD4-count amounted to 30% 
during chemotherapy, and this value should be kept in mind by the clinician when selecting 
HIV-positive patients for chemotherapy. 
In conclusion, data from this retrospective review confirmed that in a resource limited 
environment a service comparable to developed countries was provided. Data and 
observations from this study can be used for future treatment recommendations when the 
phenotype of breast cancer and the ability to complete systemic chemotherapy is offered to 
women infected with HIV.    
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ABBREVIATIONS 
AIDS:  Acquired Immune-Deficiency Virus 
AJCC:  American Joint Committee on Cancer 
ARDS:  Adult Respiratory Distress Syndrome 
ART:  Anti-Retroviral Therapy 
BRCA:  Breast Cancer susceptibility gene 1 and 2 (tumour suppressor genes)  
CD4:  Cluster of differentiation 4, a glycoprotein predominantly found on the  
surface of T-helper cells.  
CMF:  Cyclophosphamide/Methotrexate/5-Flourouracil 
CTC:  Common Toxicity Criteria  
DCIS:  Ductal Carcinoma in Situ 
EC:  4-Epiadriamycin/Cyclophosphamide 
ECOG:  Eastern Cooperative Oncology Group 
ELISA:  Enzyme-Linked Immunosorbent Assay 
EORTC: European Organization for Research and Treatment of Cancer 
ER:  Estrogen Receptor 
FEC:  5-Flourouracil/4-Epiadriamycin/Cyclophosphamide 
G-CSF:  Granulocyte-Colony Stimulating Factor 
GFR:  Glomerular Filtration Rate 
gp-120:   Glycoprotein-120 
Hb:  Hemoglobin 
HER2:  Human Epidermal Growth Factor Receptor 2  
HREC-1:   Health Research Ethics Committee 1 
HIV:  Human Immune-Deficiency Virus 
NADC:  Non-Aids Defining Cancer 
p24:  Protein 24 
NCI:  National Cancer Institute 
PR:  Progesterone Receptor 
PTB:  Pulmonary Tuberculosis 
RNA:  Ribonucleic Acid 
SD:  Standard Deviation 
SEER:  Surveillance Epidemiology End Results 
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USA:  United States of America 
WCC:  White Cell Count 
WHO:  World Health Organization 
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Addendum 1: Protocol summary. 
Breast cancer diagnosed in women with the Human Immune-deficiency 
Virus. 
Principal Investigator:  Dr. L. Langenhoven. Tygerberg Academic Hospital, Cape 
Town, SA. 
Supervisor/Co-Investigator:  Dr. P. Barnardt. Tygerberg Academic Hospital, Cape Town, 
SA. 
 
Introduction and literature review: 
HIV/AIDS is the defining pandemic of our era.1The widespread use of HAART has led to 
improved survival in a population previously at risk for early mortality. Given that breast 
cancer is the biggest global malignancy affecting the female population, it is expected that the 
number of immune-compromised survivors developing breast cancer will increase with 
time.2To date, only 48 case reports have been published on the HIV-positive patient with 
breast cancer. Initial reports suggested a more aggressive tumour, triple negative receptor 
status, a younger age at presentation, a poorer prognosis, and an inability to complete 
chemotherapy.3  
Study Objectives  
1. The primary objective of this retrospective analysis it to describe the phenotype of 
breast cancer in the HIV positive population in relation to its HIV negative control 
group. 
2. Secondary objectives include the following: 
2.1. The ability of HIV positive patients to complete standard chemotherapy regimes. 
If treatment could not be completed, the reasons for cessation and the timing 
thereof will be documented. 
2.1. The trend of the CD4 count changes during chemotherapy. 
2.3 Disease Free Survival and Time to Progression. 
 
Study design: The study will take the form of a retrospective descriptive, clinical audit and 
will be submitted as the thesis for my M.Med Rad. Onc degree.  
Inclusion Criteria:  Female patients of all ethnic groups newly diagnosed with breast cancer 
at Tygerberg Hospital during the period Jan 2010 – Dec 2011 will be eligible for inclusion. 
Exclusion Criteria: Any patient managed only with surgery, palliative radiotherapy or 
patients included in the neo-adjuvant Paclitaxel trial will be excluded from participation in the 
study. 
Methods: The cohort will be stratified into 2 subgroups: The HIV positive patient with breast 
cancer and the HIV negative patient with breast cancer. The age and stage of presentation 
will be compared between these 2 subgroups, as well as tumor characteristics such as: 
Histological subtype, grade of differentiation, receptor status, nodal status and tumour size. In 
the HIV positive group, the CD4 count, use of ART and the ability to complete planned 
treatment will be noted. The data collection sheet is attached as an addendum. 
Data Management and Statistical analysis: All the patient and treatment information will be 
collected from the patients’ hospital folders, and will be conducted at the radiotherapy 
department of Tygerberg hospital. A database using Microsoft Excel 2003 will be created for 
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the purpose of the review (Addendum). Once the data is collected it will be analyzed with the 
help of US statistician, Prof Martin Kidd.  
Time Plan and logistics:  The study will commence as soon as ethics committee approval is 
granted. Data collection is estimated to take 3 months.  
Ethical Aspects: This project will be an internal, departmental review, primarily based on 
folder reviews. Information will be collected to protect the patient confidentiality. 
 No name, date of birth or hospital folder number will be mentioned.   
 The data capture sheet will only have a study code attached 
  Identifying information linked to the study code, will be kept in a password protected 
database. 
  Access to this information will be restricted to the principal and co-investigators.  
 Access to the database as a whole will be password protected.  
 
Waiver of informed consent is requested from the ethics committee on the following grounds: 
1. Each patient in the cohort gave informed consent to the testing of their HIV status prior to 
the test being done. 
2. Patient information will be collected in such a way as to protect patient confidentiality as 
discussed. 
3. The research will produce valuable information that would benefit the HIV positive patient 
receiving treatment for breast cancer. Recommendations regarding the tolerance of 
chemotherapy and possible dose-reductions will be made. 
4. It would be impossible to trace individuals because of the retrospective nature of the 
audit. 
Publication of the results will answer many of the current controversies in terms of the 
phenotype of disease, and the tolerance of the HIV-positive patient to current treatment 
regimens. Recommendations on dose-alterations in the HIV positive patient will be made 
based on the witnessed CD4-count trend. 
Resources: No financial resources have been made available for this project. It is an M.Med 
thesis without financial incentive or interest other than those academic in nature. 
Strengths and Limitations: Describing the phenotype of breast cancer in the HIV positive 
patient is ideally suited to the South-African academic environment as SA has the highest HIV 
prevalence in the world. Ideally prospective data should be collected, in this case a limitation 
in the study design. 
References 
1. WHO Global HIV/AIDS Response 2011. Epidemic update and health sector progress towards 
Universal Access.  
http://www.unaids.org/en/media/unaids/contentassets/documents/document/2011/JC2215_Glo
bal_AIDS_Response_Progress_Reporting_en.pdf 
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96. 
3. Palan M, Shousha S et al. Breast Cancer in the Setting of HIV. Pathology Research Int  2011; 
ID 925712 
4. Sarhan, M, Hector A et al. Breast cancer in women with Human Immunodeficiency Virus 
Infection : Pathological, clinical, and prognostic implications. Journal of Women’s Health 2010; 
19:2261-2266. 
 
 
Stellenbosch University  http://scholar.sun.ac.za
  34
Addendum 2:  Protocol. 
Breast cancer diagnosed in women with the Human Immune-deficiency 
Virus. 
 
Principal Investigator: Dr. L. Langenhoven. Tygerberg Academic Hospital, Cape 
Town, SA. 
Supervisor/Co-Investigator: Dr. P. Barnardt. Tygerberg Academic Hospital, Cape Town, 
SA. 
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Introduction and Literature review 
HIV is undeniably the defining pandemic of our era.  According to the 2008 WHO statistics, it 
is estimated that more than 33.4 million people globally are infected with HIV, approximately 
70% of which reside in sub-Saharan Africa.1 With the widespread introduction of ART, the life 
expectancy of patients living with HIV/AIDS has improved dramatically. Considering that 
breast cancer is the most common cancer in women, it is projected that the number of HIV-
positive patients with breast cancer will increase in the foreseeable future.2 
The impact of HIV on breast cancer incidence, stage at presentation, response to treatment 
and treatment toxicity remains largely contentious at present. Case reports dominate the 
literature, of which 48 in total have been published. Hurley et al contributed the largest case 
series describing the treatment and outcome of 20 HIV positive patients with breast cancer.3 
A more aggressive phenotype was described in the HIV positive patient, dominated by a triple 
negative receptor status, younger age at presentation, inability to complete chemotherapy 
and greater treatment related toxicity. 
Palan et al published a report on 11 patients in 2011, all of which had a similar outcome to 
that witnessed in the HIV negative patient.4 Unfortunately these series were by American and 
European investigators, evaluating a disease relatively uncommon in their society. The South 
African experience of breast cancer in the HIV positive patient is much greater, yet no 
publication on the data has been presented for publication. 
It is the aim of this study to describe the phenotype of breast cancer in the HIV positive 
patient in terms of age and stage at presentation, tumor grade and receptor status, as well as 
tolerance to standard treatment regimens.  
Study Objectives  
The primary objective of this retrospective analysis it to describe the phenotype of breast 
cancer in the HIV positive population in relation to its HIV negative control group.  
Secondary objectives include the following: 
1. The ability of HIV positive patients to complete standard chemotherapy and 
radiotherapy regimes. If planned treatment could not be completed, the reasons for 
cessation and the timing thereof will be documented. 
2. The trend of the CD4 count changes during chemotherapy. 
3. Disease Free Survival and Time to Progression. 
 
Study design 
 
The study will take the form of a retrospective descriptive, clinical audit and will be submitted 
as the thesis for my M.Med Rad. Onc degree.  
All newly diagnosed breast cancer patients seen at Tygerberg Hospital between January 
2010 and December 2011 will be included. Consented HIV testing was introduced in 2009, 
and with the exception of a few patients, the HIV status of every new patient is known. The 
study cohort is estimated to be 800 patients over the 2 year study period, of which 75 is 
estimated to be HIV-positive. 
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Inclusion Criteria 
 All newly diagnosed patients with breast cancer at Tygerberg Hospital during the period Jan 
2010 – Dec 2011 will be eligible for inclusion 
Female patients between the ages of 18-75 years  
Patients of all ethnic groups will be included. 
Exclusion Criteria 
Any patient managed with only surgery or 
Patients managed with only palliative radiotherapy. 
Patients enrolled in the neo-adjuvant Paclitaxel trial. 
Objectives  
The primary objective of this retrospective analysis it to describe the phenotype of breast 
cancer in the HIV positive population in relation to its HIV negative control group.  
Secondary objectives include the following: 
1. The ability of HIV positive patients to complete standard chemotherapy and 
radiotherapy regimes. If planned treatment could not be completed, the reasons for 
cessation and the timing thereof will be documented. 
2. The trend of the CD4 count changes during chemotherapy. 
3. Disease Free Survival and Time to Progression. 
  
Methods 
The cohort will be stratified into 2 subgroups:  
1. The HIV-negative patient with breast cancer. 
2. The HIV-infected patient with breast cancer. 
The age and stage of presentation will be compared between these 2 subgroups, as well as 
tumor characteristics such as: 
- Histological subtype 
- Grade of differentiation 
- Receptor status 
- Her2neu expression status 
- Nodal status 
- Tumour size 
 
In the HIV positive group, the CD4 count, use of ART and the ability to complete standard 
treatment regimens will be documented. 
All the patient and treatment information will be collected from their oncology therapy folders, 
radiotherapy treatment files, TBH folders, the NHLS results database and the Clinicom patient 
administration system used at Tygerberg Hospital. It will be conducted at the radiotherapy 
department (X Block) of Tygerberg hospital. 
Stellenbosch University  http://scholar.sun.ac.za
  37
If a patient is found to be “lost to follow up” according to their hospital records, follow up 
information will be updated by telephonic contact with the patient or their immediate relatives 
to assess the patients status (alive /deceased). 
Data Management and Statistical analysis 
A database using Microsoft Excel 2003 will be created for the purpose of the review. 
(Appendix A).Once the data is collected on the database, it will be analyzed with the help of 
US statistician, Prof Martin Kidd. For descriptive purposes, frequency tables, histograms, 
means, standard deviation etc. will be used. For comparison between groups, the Chi- square 
test or ANOVA will be used depending on the types of data (continuous or categorical). Final 
decisions on which statistical techniques are most appropriate, will be made once the data 
have become available. 
Time Plan and logistics 
The study will commence as soon as ethics committee approval is granted.  
Data collection is estimated to take 3 months. 
The aim will be to finalize the analysis and study to be presented at the University 
Stellenbosch Academic Year Day in August 2012.  
Ethical Aspects 
This project will be an internal, departmental review, primarily based on folder reviews, with 
where required, a telephonic update of patient’s health status. Information will be collected in 
such away to protect the patient confidentiality. 
 No name, date of birth or hospital folder number will be mentioned.   
 The data capture sheet will only have a study code attached 
  Identifying information linked to the study code, will be kept in a password protected 
database. 
  Access to this information will be restricted to the principal and co-investigators.  
 Access to the database as a whole will be password protected.  
 
Waiver of informed consent is requested from the ethics committee on the following grounds: 
1. Each patient in the cohort gave informed consent to the testing of their HIV status 
prior to the test being done. 
2. Patient information will be collected in such a way as to protect patient confidentiality 
as discussed. 
3. The research will produce valuable information that would benefit the HIV positive 
patient receiving treatment for breast cancer. Recommendations regarding the 
tolerance of chemotherapy and possible dose-reductions will be made. 
4. It would be impossible to trace individuals because of the retrospective nature of the 
audit. 
 
5. Publication of the results will answer many of the controversies in terms of the 
phenotype of disease, and the tolerance of the HIV-positive patient to current 
treatment regimens. Recommendations on dose-alterations in the HIV positive 
patient will be made based on the witnessed CD4-count trend. 
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The database could be used in the department in the future to serve as an audit for both HIV 
positive and negative patients receiving treatment for breast cancer at Tygerberg Hospital. 
Comparison with international results could be made to ensure that the standard of care is 
acceptable and in line with what is predicted. 
Resources 
No financial resources have been made available for this project. It is a M.Med thesis and 
data collection will be done by the principal investigator. 
Strengths and Limitations 
Describing the phenotype of breast cancer in the HIV positive patient is ideally suited to the 
South-African academic environment as SA has the highest HIV prevalence in the world. 
Ideally prospective data should be collected, in this case a limitation in the study design. 
 
Bibliography 
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Addendum 3:  Approval notice by HREC-1 Committee. 
22-Mar-2012  
LANGENHOVEN, Lizanne 
 
Approval Notice New Application 
Protocol #: S12/02/048 Title: Breast cancer diagnosed in women with the 
Human Immune-deficiency Virus (HIV) 
Dear Dr Lizanne LANGENHOVEN, 
The New Application received on 17-Feb-2012, was reviewed by members of 
Health Research Ethics Committee 1 via Expedited review procedures on 13- 
Mar-2012 and was approved. Please note the following information about your 
approved research protocol: 
Protocol Approval Period: 13-Mar-2012 -13-Mar-2013 Please remember to use 
your protocol number (S12/02/048) on any documents or correspondence with the 
REC concerning your research protocol. 
Please note that the REC has the prerogative and authority to ask further questions, 
seek additional information, require further modifications, or monitor the conduct of 
your research and the consent process. 
After Ethical Review: 
Please note a template of the progress report is obtainable on www.sun.ac.za/rds 
and should be submitted to the Committee before the year has expired.The 
Committee will then consider the continuation of the project for a further year (if 
necessary). Annually a number projects may be selected randomly for an external 
audit. Translation of the consent document in the language applicable to the study 
participants should be submitted. 
Federal Wide Assurance Number: 00001372 Institutional Review Board (IRB) 
Number: IRB0005239 
The Health Research Ethics Committee complies with the SA National Health Act 
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No.61 2003 as it pertains to health research and the United States Code of Federal 
Regulations Title 45 Part 46. This committee abides by the ethical norms and 
principles for research, established by the Declaration of Helsinki, the South African 
Medical Research Council Guidelines as well as the Guidelines for Ethical Research: 
Principles Structures and Processes 2004 (Department of Health). 
Provincial and City of Cape Town Approval 
Please note that for research at a primary or secondary healthcare facility permission 
must still be obtained from the relevant authorities (Western Cape Department of 
Health and/or City Health) to conduct the research as stated in the protocol. Contact 
persons are Ms Claudette Abrahams at Western Cape Department of Health 
(healthres@pgwc.gov.za Tel: +27 21 483 9907) and Dr Hlne Visser at City Health 
(Helene.Visser@capetown.gov.za Tel: +27 21 400 3981). Research that will be 
conducted at any tertiary academic institution requires approval from the relevant 
hospital manager. Ethics approval is required BEFORE approval can be obtained 
from these health authorities. 
We wish you the best as you conduct your research.For standard REC forms and 
documents please visit: www.sun.ac.za/rds 
If you have any questions or need further help, please contact the REC office at 
0219389657. 
Included Documents: 
Synopsis  
Declaration  
Protocol  
Checklist 
Application  
CV 
 
Sincerely, 
Franklin WeberREC CoordinatorHealth Research Ethics Committee 1 
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Addendum 4:  HREC-1 Application for amendments to protocol. 
 
No 20, 17th Avenue 
Boston 
Bellville  
7530 
 
13/04/2012 
The Health Research Ethics Committee 1, 
Re:  Addendum to Protocol S12/02/048 
 Breast cancer diagnosed in women with the Human Immune-deficiency Virus  
1. Request to extend the research period as per protocol (2010-2011) to include the 
years 2008-2009 due to an unexpected lack of HIV-positive patients.   
 
2. The principal investigator was offered an educational grant (The D43 Grant) by the 
Mailman School of Epidemiology, Columbia University, New York City.  Dr. Lizanne 
Langenhoven will attend summer school in NYC during June 2012, followed by a 
month period of hands-on guidance in research ethics, epidemiology and 
biostatistics. The chosen project for assistance is the project of breast cancer 
diagnosed in women with the Human Immune-deficiency Virus.  
 
The contractual agreement between Dr. Langenhoven and Columbia University 
states that any publication arising from the educational grant has to be published with 
the following paragraph: 
 
3. Through the funding of Columbia University, a research assistant will be employed to 
assist with data collection onto a password protected database. The assistant is 
contractually bound to patient privacy, and the principal investigator accepts the 
responsibility of ensuring that her actions are professional, ethically correct, that she 
respects patient privacy and serves the medical community at a large.  
 
Regards,  
Dr. Lizanne Langenhoven 
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079 5244 754 
kibouter@yahoo.com 
Addendum 5:  HREC-2 approval of amendments to protocol. 
10-May-2012  
Barnardt, Pieter P 
 
Approved with Stipulations Amendment 
Ethics Reference #: S12/02/048 Title: Breast cancer diagnosed in women with the 
Human Immune-deficiency Virus (HIV) 
Dear Doctor Pieter Barnardt, 
The Amendment received on 13-Apr-2012, was reviewed by members of Health Research 
Ethics Committee 2 via Expedited review procedures on 18-Apr-2012. 
Sincerely, 
 
Mertrude Davids 
REC Coordinator 
Health Research Ethics Committee 2 
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Addendum 6: Approval to conduct research at Tygerberg H
Provincial Research Policy and Tygerberg Hospital Notice No. 40/09.
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ospital in accordance with the 
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